CULLINAN THERAPEUTICS INC (CGEM)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies targeting unmet medical needs.
What CULLINAN THERAPEUTICS INC does
Cullinan Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutic candidates across multiple disease areas. The company is in the preclinical and clinical development stages with a portfolio of product candidates, including a collaboration with Taiho Pharmaceutical Co., Ltd. The company does not yet have approved products on the market and generates no meaningful revenue from product sales.
Themes: ["Clinical-stage therapeutics","Drug discovery and development","Biopharmaceutical R&D","Strategic collaborations"]
Fundamentals
- Price$18.38 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+150.7% as of 2026-07-09 close
- Net margin-346.2% as of 2026-07-10
- ROE-51.4% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-0.00 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial success is uncertain; the company's product candidates may fail to demonstrate efficacy or safety, delaying or preventing regulatory approval and commercialization","Regulatory approval is not guaranteed; the company depends on obtaining and maintaining regulatory clearances for investigational new drug applications and new drug applications on unpredictable timelines","The company is unprofitable with significant ongoing losses and cash burn, requiring additional financing to continue operations and fund clinical development programs"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.